Utility of dose frequency adjustment in tocilizumab administration for rheumatoid arthritis

Shuntaro Saito, Yuko Kaneko, Keisuke Izumi, Tsutomu Takeuchi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective. To assess the utility of dose frequency adjustment of tocilizumab (TCZ) in rheumatoid arthritis (RA). Methods. Patients who received TCZ at 3-week (n = 24) or 5-week (n = 61) interval were evaluated. Results. Disease Activity Score at 28 joints based on erythrocyte sedimentation rate in the 3-week group significantly improved after 3 administrations at 3-week intervals (from 4.2 to 2.7, p = 0.001). Forty-five of the patients in the 5-week group (74%) successfully continued 5-week interval administration without disease exacerbation. Lower C-reactive protein level at TCZ initiation and shorter duration to remission achievement were key to successful dose frequency reduction. Conclusion. Adjusting the dose frequency of intravenous TCZ is a useful strategy.

Original languageEnglish
Pages (from-to)553-557
Number of pages5
JournalJournal of Rheumatology
Volume44
Issue number5
DOIs
Publication statusPublished - 2017 May 1

Fingerprint

Social Adjustment
Rheumatoid Arthritis
Blood Sedimentation
C-Reactive Protein
Disease Progression
Joints
tocilizumab

Keywords

  • Arthritis
  • Rheumatoid
  • Tocilizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Cite this

Utility of dose frequency adjustment in tocilizumab administration for rheumatoid arthritis. / Saito, Shuntaro; Kaneko, Yuko; Izumi, Keisuke; Takeuchi, Tsutomu.

In: Journal of Rheumatology, Vol. 44, No. 5, 01.05.2017, p. 553-557.

Research output: Contribution to journalArticle

@article{44a6d5e067864b01a1befb54d290cd0f,
title = "Utility of dose frequency adjustment in tocilizumab administration for rheumatoid arthritis",
abstract = "Objective. To assess the utility of dose frequency adjustment of tocilizumab (TCZ) in rheumatoid arthritis (RA). Methods. Patients who received TCZ at 3-week (n = 24) or 5-week (n = 61) interval were evaluated. Results. Disease Activity Score at 28 joints based on erythrocyte sedimentation rate in the 3-week group significantly improved after 3 administrations at 3-week intervals (from 4.2 to 2.7, p = 0.001). Forty-five of the patients in the 5-week group (74{\%}) successfully continued 5-week interval administration without disease exacerbation. Lower C-reactive protein level at TCZ initiation and shorter duration to remission achievement were key to successful dose frequency reduction. Conclusion. Adjusting the dose frequency of intravenous TCZ is a useful strategy.",
keywords = "Arthritis, Rheumatoid, Tocilizumab",
author = "Shuntaro Saito and Yuko Kaneko and Keisuke Izumi and Tsutomu Takeuchi",
year = "2017",
month = "5",
day = "1",
doi = "10.3899/jrheum.161047",
language = "English",
volume = "44",
pages = "553--557",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "5",

}

TY - JOUR

T1 - Utility of dose frequency adjustment in tocilizumab administration for rheumatoid arthritis

AU - Saito, Shuntaro

AU - Kaneko, Yuko

AU - Izumi, Keisuke

AU - Takeuchi, Tsutomu

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Objective. To assess the utility of dose frequency adjustment of tocilizumab (TCZ) in rheumatoid arthritis (RA). Methods. Patients who received TCZ at 3-week (n = 24) or 5-week (n = 61) interval were evaluated. Results. Disease Activity Score at 28 joints based on erythrocyte sedimentation rate in the 3-week group significantly improved after 3 administrations at 3-week intervals (from 4.2 to 2.7, p = 0.001). Forty-five of the patients in the 5-week group (74%) successfully continued 5-week interval administration without disease exacerbation. Lower C-reactive protein level at TCZ initiation and shorter duration to remission achievement were key to successful dose frequency reduction. Conclusion. Adjusting the dose frequency of intravenous TCZ is a useful strategy.

AB - Objective. To assess the utility of dose frequency adjustment of tocilizumab (TCZ) in rheumatoid arthritis (RA). Methods. Patients who received TCZ at 3-week (n = 24) or 5-week (n = 61) interval were evaluated. Results. Disease Activity Score at 28 joints based on erythrocyte sedimentation rate in the 3-week group significantly improved after 3 administrations at 3-week intervals (from 4.2 to 2.7, p = 0.001). Forty-five of the patients in the 5-week group (74%) successfully continued 5-week interval administration without disease exacerbation. Lower C-reactive protein level at TCZ initiation and shorter duration to remission achievement were key to successful dose frequency reduction. Conclusion. Adjusting the dose frequency of intravenous TCZ is a useful strategy.

KW - Arthritis

KW - Rheumatoid

KW - Tocilizumab

UR - http://www.scopus.com/inward/record.url?scp=85018287459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018287459&partnerID=8YFLogxK

U2 - 10.3899/jrheum.161047

DO - 10.3899/jrheum.161047

M3 - Article

C2 - 28298563

AN - SCOPUS:85018287459

VL - 44

SP - 553

EP - 557

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 5

ER -